We tested the hypothesis that inhibiting nitric oxide production either before or during transient focal ischemia affects early postischemic brain injury.
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Background and Purpose We tested the hypothesis that inhibiting nitric oxide production either before or during transient focal ischemia affects early postischemic brain injury.
Methods Halothane-anesthetized cats underwent 1 hour of left middle cerebral artery occlusion plus 3 hours of reperfusion. Pretreatment groups received either intravenous N"-nitro-L-arginine methyl ester (L-NAME; 10 mg/kg, n=10) or an equal volume of diluent (10 mL saline, n=10) over 30 minutes before ischemia. Posttreatment groups received intravenous L-NAME (10 mg/kg) over 30 minutes from 45 minutes of ischemia to 15 minutes of reperfusion (n=10) or intravenous L-NAME (10 mg/kg) plus L-arginine (200 mg/kg) over the same period followed by continuous L-arginine infusion (200 mg/kg per hour) for the remainder of reperfusion (n=10).
Results Microsphere-determined blood flow to ipsilateral caudate nucleus and inferior temporal cortex decreased to the same extent during ischemia and recovered to the same extent during reperfusion in the four groups. Triphenyltetrazoliumdetermined injury volume of ipsilateral caudate nucleus in cats U nder normal circumstances nitric oxide (NO) is important in the control of cerebral vascular tone, 1 platelet aggregation, and adhesion 2 and may act as a neuronal messenger. 3 The role of NO in the mechanism of brain injury following transient focal ischemia has not yet been completely elucidated. A role for NO in neurotoxicity has been suggested by the observation that TV-methyl-D-aspartate (NMDA)-induced injury to neurons in culture 4 and in slices 5 is blocked by the inhibition of production of NO.
During ischemia there is release of excitatory amino acids into the extracellular space. 6 Once released, excitatory amino acids may act at NMDA or non-NMDA receptors to stimulate NO synthase (NOS) and increase production of NO. 710 Using a porphyrinic microsensor, Malinski et al u have presented evidence for increased NO production in brain during transient focal ischemia. Once formed, NO may act to combine with superoxide anion, which is also produced during transient ischemia, 12 and form peroxynitrite. 13 Peroxynitrite may in treated with L-NAME before or during ischemia (42±7% and 42±3% of caudate nucleus, respectively; mean±SE) was less (P<.05) compared with that in cats pretreated with saline (72±5%) or cats treated with L-NAME plus L-arginine (68±5%). Ipsilateral cerebral hemispheric injury volume was similar among the four groups (23±5%, 13±3%, 18±5%, and 29±5% of hemisphere in groups treated with L-NAME before ischemia and during ischemia, the saline-treated group, and the group treated with L-NAME plus L-arginine, respectively).
Conclusions Inhibition of nitric oxide synthase decreases caudate injury volume from transient focal cerebral ischemia in cats. The beneficial effect is reversed by L-arginine and is not caused by favorable redistribution of blood flow during ischemia and reperfusion. Because L-NAME was efficacious when administered at reperfusion, nitric oxide generated during reperfusion appears to contribute to caudate injury. turn decompose to form a strong oxidant with a reactivity similar to that of hydroxyl radical. 14 If this peroxynitrite mechanism is of physiological significance, one would expect that inhibiting accumulation of superoxide anion or decreasing production of NO would be associated with decreased brain injury after transient focal ischemia. In support of this hypothesis, we have demonstrated that treatment with either superoxide dismutase before transient focal ischemia or with an inhibitor of NOS before permanent focal ischemia decreased caudate injury in cats. 1516 Likewise, others 1719 have demonstrated that inhibiting NOS decreases cortical injury associated with prolonged focal ischemia in mice and rats. However, inconsistent with this hypothesis are the findings that, in spontaneously hypertensive rats, inhibition of NOS results in increased brain injury 20 and that administration of L-arginine, which may act to increase production of NO, results in decreased brain injury after permanent focal ischemia. 21 Based on these findings we tested the hypothesis that administration of the long-acting inhibitor of NOS, Af"-nitro-L-arginine methyl ester (L-NAME), before or at the end of transient focal ischemia alleviates early brain injury. To assess the question of specificity of the L-NAME response for an NO-mediated mechanism, 22 we also examined whether administration of L-arginine, by guest on December 24, 2017 http://stroke.ahajournals.org/ Downloaded from the substrate for NOS, reverses any beneficial effect of L-NAME on brain injury. Regional cerebral blood flow (CBF) and somatosensory evoked potentials (SEP) were measured during cerebral ischemia and reperfusion to determine if changes in these values could account for any beneficial effect detected with drug treatment.
Materials and Methods
Forty-nine female cats weighing 2.2 to 4.3 kg were used. After anesthesia was induced with halothane in oxygen, cats were orally intubated and mechanically ventilated to maintain Paco 2 at approximately 35 to 40 mm Hg. Anesthesia was maintained with halothane (0.5% to 1.5%) in oxygen-enriched air (Fio 2 , 0.35 to 0.40). Anesthetic concentration was not altered during the experimental protocol. Pancuronium bromide (0.2 mg/kg IV) was administered as a single dose for muscle relaxation to prevent movement during electrocautery and muscle artifact during evoked potential monitoring.
Both femoral veins were catheterized for infusion of lactated Ringer's solution and drugs. Catheters were placed in the descending aorta via a femoral artery for blood pressure measurement, arterial blood gas sampling, and for withdrawal of reference blood samples during injection of radiolabeled microspheres. After left thoracotomy, a catheter was inserted into the left atrium for injection of radiolabeled microspheres. The cat was turned prone and its head positioned in a stereotaxic frame approximately 4 cm higher than its heart. A thermistor placed in the right temporal epidural space was used to estimate brain temperature. Epidural temperature was maintained at 38.0±0.5°C using a warmed water blanket and a heating lamp. The left middle cerebral artery (MCA) was exposed by a transorbital approach using microsurgical techniques. 23 To produce focal ischemia, the left MCA was occluded near its origin from the intracranial carotid artery with a microvascular clip for 1 hour. At 1 hour of ischemia, the microvascular clip on the MCA was removed. Reperfusion lasted 3 hours.
Arterial blood pressure and end-tidal CO 2 were continuously monitored. Arterial pH, Paco 2 , and Pao 2 were measured with a self-calibrating Radiometer electrode system (ABL 3). Hemoglobin and arterial oxygen content were measured with a hemoximeter (Radiometer, model OSM3). Blood glucose was measured with a glucose analyzer (model 2300A, Yellow Springs Instruments). A multichannel signal averager (model CA-1000, Nicolet Biomedical Instruments) was used to measure the SEP with foreleg stimulation as previously described. 15 - 23 The amplitude to the peak of the first major negative wave was measured from the peak of the preceding positive wave.
Regional CBF was measured with radiolabeled microspheres (16±0.5 fim in diameter; Du Pont-NEN Products) using the reference withdrawal method. 24 Six radioactive isotopes ( 153 Gd, " 4m In, 113 Sn,
IO3
Ru, 95 Nb, "Sc) were injected in random sequence in each animal. Approximately 1.5xlO 6 microspheres were injected into the left atrium over a 20-second period, followed by a 5-mL saline flush. The reference blood sample was withdrawn from the aorta at 1.9 mL/min beginning 30 seconds before the injection and continuing for 90 seconds after the saline flush.
After baseline measurements were obtained, cats were assigned to one of four groups (n=10 each). Each group was exposed to 60 minutes of left MCA occlusion and 3 hours of reperfusion. The control group (pre-saline) received 10 mL 0.9% NaCl over 30 minutes by continuous intravenous infusion that ended 30 minutes before MCA occlusion. The pretreatment group (pre-L-NAME) received L-NAME (10 mg/kg in 10 mL saline) over 30 minutes by continuous intravenous infusion that ended 30 minutes before MCA occlusion. We have found previously that this dose of L-NAME produced rapid and complete inhibition of NOS activity in cats. 16 In both of these groups, measurements of CBF, SEP, arterial blood gases, and arterial pressure were repeated just before MCA occlusion. The SEP was recorded at 5 minutes of MCA occlusion and then every 30 minutes for the duration of ischemia. Cats that did not achieve at least 75% reduction in SEP amplitude with MCA occlusion were excluded at the time of the experiment, and data were not analyzed (n=3, presaline; n = l , pre-L-NAME group). Arterial blood gases, arterial pressure, and CBF were measured at 30 and 60 minutes of MCA occlusion and 2 and 3 hours of reperfusion.
In the posttreatment groups MCA occlusion was performed immediately after obtaining baseline measurements. After 45 minutes of MCA occlusion, animals were treated with either L-NAME alone (10 mg/kg in 10 mL saline; post-L-NAME group) or L-NAME (10 mg/kg) plus L-arginine (200 mg/kg; both L-NAME and L-arginine in a total volume of 10 mL saline; L-NAME+ARG group) by continuous intravenous infusion for the following 30 minutes (ie, last 15 minutes of MCA occlusion and first 15 minutes of reperfusion). In the L-NAME+ARG group, after the initial drug infusion, L-arginine (200 mg/kg per hour in saline) was administered by continuous intravenous infusion for the remainder of the experimental protocol (5 mL/h). All four groups received the same infusion rate of saline or drug (5 mL/h) throughout reperfusion. In both posttreatment groups, the SEP was recorded at 5 minutes of MCA occlusion and then every 30 minutes for the duration of ischemia and reperfusion. Cats that did not achieve at least 75% reduction in SEP amplitude with MCA occlusion were immediately excluded from the protocol (n=2, post-L-NAME; n=3, L-NAME+ARG). Arterial blood gases, arterial pressure, and CBF were measured at 30 and 60 minutes of left MCA occlusion and at 1, 2, and 3 hours of reperfusion.
At 3 hours of reperfusion, cats in all groups were killed with intravenous potassium chloride. The brain was removed and cut immediately into 12 uniform coronal sections 3 mm thick to estimate brain injury with the 2,3,5 -triphenyltetrazolium chloride (TTC; Sigma Chemical Co) technique 2526 as previously described in our laboratory.
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- 27 After injury volume was estimated, the slices of brain were placed in 10% buffered formalin for 1 to 2 days. Ipsilateral and contralateral temporal and parietal lobe areas of the middle four slices were subsequently sectioned into three cortical gray matter regions (inferior temporal, lateral temporal-parietal, and superior parietal) and one white matter region for regional CBF determinations. Brain was also sectioned into ipsilateral and contralateral caudate nucleus, ipsilateral and contralateral hippocampus, brain stem, and cerebellum. The arterial microsphere reference samples and weighed tissue specimens were counted in a multichannel autogamma scintillation spectrometer (Minaxi model 5530, Packard Instruments). The overlap of activity among isotopes was corrected by differential spectroscopy, and blood flow was calculated by the reference sample technique. 24 Values are expressed as mean±SE. Statistical comparison to assess changes in measured physiological variables within groups was performed by repeated-measures ANOVA. The effect of experimental manipulation on blood flow within each group was determined with paired Student's / test with Bonferroni correction. Differences among groups were determined with unpaired Student's t test with Bonferroni correction. Statistical differences were considered significant at f<.05.
Results
There were no significant differences among the four groups in baseline values of arterial pH (approximately 7.41), Paco 2 (approximately 39 mm Hg), Pao 2 (approximately 160 mm Hg), hemoglobin concentration (approximately 11 g/dL), or glucose concentration (approximately 110 mg/dL). There were no physiologically Values are given as mm Hg, mean±SE. L-MCAO indicates left middle cerebral artery occlusion; L-NAME, A/"-nitro-L-arginine methyl ester; Pre-saline, 10 mL saline IV 30 minutes before L-MCAO (n=10); Pre-L-NAME, L-NAME (10 mg/kg) 30-minute infusion ending 30 minutes before L-MCAO (n=10); Post-L-NAME, L-NAME (10 mg/kg) infusion between 45 minutes of L-MCAO and 15 minutes of reperfusion (n=10); and Post-L-NAME+ARG, L-NAME (10 mg/kg) and L-arginine (200 mg/kg) infused together between 45 minutes of L-MCAO and 15 minutes of reperfusion followed by continuous L-arginine (200 mg/kg per hour) infusion (n=10).
*P<.05 compared with baseline; tPs.05 compared with pre-saline group; tPs.05 post-L-NAME compared with post-L-NAME+ARG group.
significant changes over time or between groups throughout the experimental protocol. Mean arterial pressure increased after L-NAME in pre-and post-L-NAME groups but not in the post-L-NAME+ARG group (Table 1) .
Before ischemia, L-NAME caused a generalized decrease in regional CBF in the pre-L-NAME group in both cortical (Table 2 ) and subcortical regions (Table  3) . Drug treatment did not affect the extent of blood flow reduction during left MCA occlusion in ipsilateral inferior temporal cortex and lateral temporal-parietal cortex (Table 2) . However, during left MCA occlusion blood flow to ipsilateral superior parietal cortex was lower in the pre-L-NAME group compared with the pre-saline group. The level of blood flow to ipsilateral caudate nucleus during ischemia was similar in the four groups (Table 3) . Left MCA occlusion did not affect blood flow to contralateral brain regions.
Treatment with L-NAME near the end of ischemia reduced blood flow to contralateral regions including the caudate nucleus, inferior temporal cortex, superior parietal cortex, hippocampus, and to the cerebellum and brain stem compared with baseline values but not compared with values at the same time in cats treated with saline (Tables 2 and 3 ). During reperfusion, blood flow to all ipsilateral cortical regions was similar among groups, whereas blood flow to contralateral cortex was lower in the pre-and post-L-NAME groups than in the saline group.
Baseline amplitude (pre-saline, 83±15 /AV; pre-L-NAME, 82±10 ixV; post-L-NAME, 68±5 juV; post-L-NAME+ARG, 91 + 15 /J.V) and latency (pre-saline, 12.7±0.3 milliseconds; pre-L-NAME, 12.5±0.2 milliseconds; post-L-NAME, 12.2±0.2 milliseconds; post-L-NAME+ARG, 11.9±0.3 milliseconds) of the primary cortical SEP were not different among groups. Ipsilateral SEP amplitudes were suppressed to the same extent during left MCA occlusion and showed similar recovery in all groups (Table 4) . However, SEP amplitudes over the contralateral somatosensory cortex showed no change during 1 hour of left MCA occlusion followed by 3 hours of reperfusion in the four groups. In addition, all cats had normal latency of the wave measured over the second cervical vertebra throughout the protocol.
Injury volume of the caudate nucleus in pre-salinetreated cats (189±21 mm 3 ) was greater than that in cats treated with L-NAME either before (pre-L-NAME, 115 ±20 mm . When expressed as a percentage of total individual caudate volume, injury volume in the pre-and post-L-NAME groups was less than the injury volume in the pre-saline and post-L-NAME+ARG groups (Fig 1) . Ipsilateral cerebral hemispheric injury volume was not significantly different among the four groups when expressed in terms of absolute units (pre-saline, 1611±454 mm 3 , pre-L-NAME, 2101±423 mm (Fig  1) . When hemispheric injury volume was analyzed separately for each of 12 coronal sections, there was also no difference when compared with the pre-saline group (Fig 2) . However, analysis of caudate nucleus demonstrated a group effect for both pre-L-NAME and post-L-NAME compared with the pre-saline group (two-way ANOVA, / > <.05) (Fig 2) . No cat in either group demonstrated injury in the right caudate nucleus or right hemisphere.
Discussion
This study demonstrates that in cats intravenous administration of L-NAME either before or at the end of transient MCA occlusion results in partial protection from injury in the caudate nucleus but not in the cerebral hemispheres. Protection by L-NAME administered at the end of ischemia was prevented by coadministration of L-arginine. Protection from injury does not appear to be due to a favorable redistribution of blood flow during MCA occlusion despite increased arterial pressure and is not correlated with improved recovery of SEP amplitude.
The role of NO in the mechanism of brain injury from focal ischemia and reperfusion is controversial. In normotensive rats, some laboratories 1719 have demonstrated that inhibiting NOS decreases cortical injury associated with prolonged focal ischemia in mice and rats. Others 28 have found that NOS inhibition does not affect infarct volume after permanent focal ischemia, although the efficacy of NOS inhibition following L-NAME was not assessed. In spontaneously hypertensive rats, in contrast, inhibition of NOS results in Values are given as mL/min per 100 g, mean±SE. L-MCAO indicates left middle cerebral artery occlusion; L-NAME, A/"-nitro-L-arginine methyl ester; Pre-saline, 10 mL saline IV 30 minutes before L-MCAO (n=10); Pre-L-NAME, L-NAME (10 mg/kg) 30-minute infusion ending 30 minutes before L-MCAO (n=10); Post-L-NAME, L-NAME (10 mg/kg) infusion between 45 minutes of L-MCAO and 15 minutes of reperfusion (n=10); and Post-L-NAME+ARG, L-NAME (10 mg/kg) plus L-arginine (200 mg/kg) infused together between 45 minutes of L-MCAO and 15 minutes of reperfusion followed by continuous L-arginine (200 mg/kg per hour) infusion (n=10).
*P<.05 compared with baseline; tPs.05 compared with pre-saline group; $£<.O5 post-L-NAME compared with post-L-NAME+ARG group. increased brain injury. 20 An important difference in our study compared with previous studies is that none of these previous studies have evaluated a model of transient focal ischemia, and none have tested the efficacy of nitroarginine analogues administered at the end of ischemia. The present finding that administration of L-NAME either before ischemia or before reperfusion decreased caudate injury volume, taken together with our previous finding that L-NAME pretreatment also reduces caudate injury during permanent focal ischemia, 16 suggests that NO production is important in the mechanism of caudate injury during both focal ischemia and reperfusion.
Malinski et al 11 have demonstrated increased accumulation of NO during the initial period of transient focal ischemia and of reperfusion. The mechanism for in- Values are given as mL/min per 100 g, mean+SE. L-MCAO indicates left middle cerebral artery occlusion; L-NAME, A/"-nitro-L-arginine methyl ester; Pre-saline, 10 mL saline IV 30 minutes before L-MCAO (n=10); Pre-L-NAME, L-NAME (10 mg/kg) 30 minute infusion ending 30 minutes before L-MCAO (n=10); Post-L-NAME, L-NAME (10 mg/kg) infusion between 45 minutes of L-MCAO and 15 minutes of reperfusion (n=10); Post-L-NAME+ARG, L-NAME (10 mg/kg) plus L-arginine (200 mg/kg) infused together between 45 minutes of L-MCAO and 15 minutes of reperfusion followed by continuous L-arginine (200 mg/kg per hour) infusion (n=10).
*P<.05 compared with baseline; tP<.05 compared with pre-saline group; +PS.05 post-L-NAME compared with post-L-NAME+ARG group.
creased accumulation of NO was presumably the result of increased NOS activity rather than decreased NO clearance. Constitutive NOS is an enzyme that catalyzes the conversion of L-arginine to L-citrulline and NO in the presence of calcium, calmodulin, nicotinamide adenine dinucleotide phosphate, and tetrahydrobiopterin. 29 - 30 In brain, NO may be produced by NOS present in vascular endothelium, 31 astrocytes, 32 and neurons, including perivascular neurons. 
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Values are given as percent of baseline value, mean±SE. L-MCAO indicates left middle cerebral artery occlusion; L-NAME, A/"-nitro-L-arginine methyl ester; Pre-saline, 10 mL saline IV 30 minutes before L-MCAO (n=10); Pre-L-NAME, L-NAME (10 mg/kg) 30-minute infusion ending 30 minutes before L-MCAO (n=10); Post-L-NAME, L-NAME (10 mg/kg) infusion between 45 minutes of L-MCAO and 15 minutes of reperfusion (n=10); and Post-L-NAME+ARG, L-NAME (10 mg/kg) plus L-arginine (200 mg/kg) infused together between 45 minutes of L-MCAO and 15 minutes of reperfusion followed by continuous L-arginine (200 mg/kg per hour) infusion <n=10).
*P<.05 compared with baseline. There were no differences between groups.
caudate as compared with pretreatment. This suggests that NO produced during reperfusion is important in the pathophysiology of striatal injury produced by transient focal ischemia. Enhanced NO production during reperfusion may be attributable to persistent elevation of excitatory amino acids during reperfusion 37 at a time when oxygen, which is necessary for production of NO by NOS, would be available. Evidence that excitatory amino acids play a role in postischemic brain injury comes from the finding that postischemic administration of a non-NMDA glutamate receptor antagonist, NBQX [2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinox- aline], 38 prevented brain injury after global ischemia. In addition, activity of NOS is primarily regulated by intracellular calcium, which presumably remains elevated during early reperfusion.
Another potential mechanism for production of NO during reperfusion may be related to flow-mediated vasodilation during postischemic hyperemia. 39 ' 40 Regardless of the mechanism for NO production, during reperfusion NO may react with superoxide anion, which is also produced in high concentration during reperfusion 12 to produce peroxynitrite. 13 Peroxynitrite may in turn decompose to form a strong oxidant 14 and result in significant brain injury.
We previously found that a 10-mg/kg dose of L-NAME completely inhibited cortical NOS activity in cats over a 4-hour period. 16 However, L-NAME has also been demonstrated to be a muscarinic receptor antagonist in isolated rabbit coronary artery as well as in isolated strips of canine colonic smooth muscle. 22 To determine the specificity of L-NAME in our study, we administered a large dose of the L-arginine substrate for the enzymatic reaction to competitively reverse the effects of L-NAME. Because the beneficial effect of L-NAME in our study was prevented by coadministration of L-arginine, our data indicate a specific role for NO in the mechanism of early caudate injury following transient focal ischemia.
Treatment with L-NAME produces an increase in arterial pressure. Before ischemia, inhibition of NOS caused a decrease in blood flow that we have previously demonstrated not to be associated with an alteration in cerebral oxygen consumption. 41 During ischemia, increased arterial pressure in the L-NAME pretreatment group may result in less severe ischemia during MCA occlusion. However, in our study L-NAME or the associated hypertension did not significantly alter the degree of ischemia in any group. Instead, L-NAME even caused a decrease in CBF to many regions not supplied by the left MCA when L-NAME was administered near the end of the ischemia period. However, the postischemic reduction in CBF in the L-NAMEtreated groups compared with the saline-treated group was less severe than what has been reported in L-NAME-treated rats after bilateral carotid occlusion. 42 Taken together these studies indicate that the mechanism for decreased striatal injury after transient focal ischemia by L-NAME is not due to improved distribution of blood flow during MCA occlusion or reperfusion.
Although we observed reduced injury in caudate, we failed to demonstrate protection in cortex. Several explanations for this difference may be considered. First, the distribution of NOS may be greater in caudate nucleus. 43 Second, blood flow in inferior temporal cortex during ischemia was 20 ±6 mL/min per 100 g in the pre-L-NAME group and 30±4 mL/min per 100 g in the pre-saline group. Although there was no significant group difference, lower blood flow in some of the individual cats in the pre-L-NAME group may have masked a direct neuroprotective effect of the drug.
Third, hemisphere injury volume was 1093 ±231 mm 3 in the post-L-NAME group compared with 1611±454 mm 3 in the pre-saline group. In this case, we cannot exclude that a significant difference would be revealed by a larger sample size to improve statistical power or by a duration of ischemia greater than 60 minutes to increase the size of the injury volume in the control group. Furthermore, comparison of the hemisphere injury volume in the post-L-NAME+Arg group (2552+512 mm 3 ) with that of the post-L-NAME group attained a value of /'=0.0183 by / test, which after Bonferroni correction for six possible comparisons among four groups had a corrected value of P = . l l . Therefore, we cannot exclude a type-II statistical error indicating that augmentation of the L-arginine-NO pathway adversely influences the extent of injury in the cortex.
Our finding that inhibition of NOS decreased early caudate injury after transient focal ischemia is consistent with our previous finding that NOS inhibition decreased caudate injury after permanent focal ischemia in cats. 16 Others have also reported decreased cortical injury after prolonged focal ischemia in rats 18 -19 and mice. 17 However, these data are inconsistent with two studies completed in spontaneously hypertensive rats where L-arginine decreases brain injury, 21 and inhibition of NOS increases brain injury. 20 This apparent inconsistency may result from altered response to NOS inhibition or to administration of L-arginine in genetically hypertensive rats. Consistent with this hypothesis is the finding of impaired endothelium-dependent cerebral vasodilation in spontaneously hypertensive rats.
-
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" 46 In addition, genetic hypertension is associated with altered metabolism of L-arginine, 47 increased susceptibility to brain injury following focal ischemia because of decreased ability to develop an adequate collateral circulation, 48 and an altered cyclic guanosine 3',5'-cyclic monophosphate pathway in cerebral blood vessels. 49 Conversely, we cannot exclude that reperfusion beyond 3 hours would lead to greater evolution of caudate injury in our model and loss of an early protective effect.
In conclusion, these data indicate that L-NAME treatment either before or at the end of transient focal ischemia alleviates early neuronal injury of caudate nucleus in cats anesthetized with halothane. Beneficial effects of L-NAME could be prevented by coadministration of L-arginine, which is consistent with the drug acting on NOS. Blood flow was decreased to a similar degree in all groups during MCA occlusion. The mechanism of protection for L-NAME is related to decreased production of NO and not to hypertensioninduced favorable redistribution of blood flow during MCA occlusion. Because treatment near the end of ischemia was as effective as pretreatment, NO production during reperfusion appears to contribute to striatal injury after temporary focal ischemia.
